Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension

被引:14
|
作者
Coca, A
Sobrino, J
Soler, J
Felip, A
Pelegrí, A
Mínguez, A
Vila, J
de la Sierra, A
Plana, J
机构
[1] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, E-08036 Barcelona, Spain
[2] Catalan Community Hosp, Hypertens Res Fdn, Barcelona, Spain
[3] Hosp Esperit Sant, Santa Coloma de Gramenet, Spain
[4] Ctr Hosp, Manresa, Spain
[5] Hosp Mataro, Maresme, Spain
[6] Hosp Sagrat Cor, Barcelona, Spain
[7] Gen Hosp, Igualada, Spain
[8] Hosp Municipal Badalona, Badalona, Spain
[9] Hosp Sant Camil, Sant Pere De Ribes, Spain
关键词
ambulatory blood pressure monitoring hypertension; losartan/hydrochlorothiazide fixed combination; smoothness index; trough-to-peak ratio;
D O I
10.1097/00005344-200206000-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The once-daily fixed combination of losartan 100 mg/hydrochlorothiazide 25 mg was evaluated for safety and efficacy in a multicenter open study by using 24-h ambulatory blood pressure monitoring in untreated patients with moderate-to-severe essential hypertension or patients with uncontrolled hypertension despite treatment with monotherapy or low-dose combination. After a 2-week washout period, 41 patients (22 men, 19 women) aged 34-74 years, showing a mean daytime blood pressure >135/85 mmHg, were treated with losartan 100 mg/hydrochlorothiazide 25 for 8 weeks. Ambulatory blood pressure was monitored at the end of the washout period and during the last week of treatment. A significant reduction in the average values of clinic blood pressure (from 169.9 +/- 13.5 mmHg to 139.5 +/- 15.6 mm Hg, p < 0.001 for systolic blood pressure [SBP] and from 102.2 +/- 7.1 mm Hg to 85.1 +/- 9.5 mm Hg, p < 0.001 for diastolic blood pressure [DBPI) was observed after treatment in the whole group of 41 patients. Likewise, average values of both 24-h SBP and 24-h DBP were significantly reduced (from 145.7 +/- 13.1 mm Hg to 128.3 +/- 14.6 mm Hg, p < 0.001 for 24-h SBP, and from 90.3 +/- 7.3 mm Hg to 79.2 +/- 8.6 mm Hg, p < 0.001 for 24-h DBP). The average lowering at peak was 20.2 +/- 11.8 mm Hg for 24-h SBP and 12.1 +/- 7.4 mm Hg for 24-h DBP, whereas the lowering at trough was 17.8 +/- 12.0 mm Hg and 10.4 +/- 8.1 mm Hg, respectively. The trough-to-peak ratio (TIP) was 0.88 for SBP and 0.86 for DBP, and the smoothness index was 7.36 for SBP and 6.37 for DBP. The response rate was 87.8% (blood pressure lowering >5 min Hg of either 24-h SBP or 24-h DBP average values). Among responders, T/P ratio was 0.89 for SBP and 0.87 for DBP, and the smoothness index was 8.09 for SBP and 7.15 for DBP. No side effects or changes in metabolic parameters were observed, The fixed combination of losartan 100 mg/hydrochlorothiazide 25 was very effective and well tolerated.
引用
收藏
页码:824 / 833
页数:10
相关论文
共 16 条
  • [1] Trough-to-peak ratio, smoothness index, and circadian profile after treatment with losartan 100/hydrochlorothiazide 25 fixed combination in essential hypertension
    Coca, A
    Sobrino, J
    Soler, J
    Felip, A
    Pelegri, A
    Minguez, A
    Vila, J
    De la Sierra, A
    Plana, J
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 : S159 - S159
  • [2] Trough-to-peak ratio and circadian blood pressure profile after treatment with once-daily extended-release diltiazem, 240 mg, in patients with mild-to-moderate essential hypertension
    Coca, A
    Sobrino, J
    Soler, J
    Modol, J
    Palos, MA
    Minguez, A
    Esque, J
    Plana, J
    Cases, M
    Closas, J
    delaSierra, A
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (03) : 316 - 322
  • [3] Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension
    Coca, A
    Calvo, C
    Sobrino, J
    Gómez, E
    López-Paz, JE
    Sierra, C
    Bragulat, E
    de la Sierra, A
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (11) : 2849 - 2864
  • [4] Evaluation of once-daily irbesartan 300 mg/hydrochlorothiazide 25 mg on the circadian blood pressure profile in essential hypertension
    Coca, A
    Calvo, C
    Sobrino, J
    Sierra, C
    López-Paz, JE
    Gómez-Angelats, E
    Bragulat, E
    de la Sierra, A
    [J]. JOURNAL OF HYPERTENSION, 2003, 21 : S270 - S270
  • [5] Smooth blood pressure control with valsartan/hydrochlorothiazide in patients with hypertension:: Comparison of the smoothness index and the trough:peak ratio
    Zappe, D.
    Meng, X.
    Levy, D.
    Jin, J.
    Daley, W.
    [J]. JOURNAL OF HYPERTENSION, 2007, 25 : S309 - S309
  • [6] Smooth blood pressure control with valsartan/hydrochlorothiazide in patients with hypertension:: Comparison of the smoothness index and the trough:peak ratio
    Zappe, D.
    Meng, X.
    Levy, D.
    Jin, J.
    Daley, W.
    [J]. JOURNAL OF HYPERTENSION, 2007, 25 : S309 - S309
  • [7] Effect of the fixed combination of irbesartan 300 mg/hydrochlorothiazide 25 mg on the circadian blood pressure profile in essential hypertension
    Coca, A
    Calvo, C
    Sabrino, J
    Sierra, C
    López-Paz, JE
    Gómez-Angelats, E
    Bragulat, E
    de la Sierra, A
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 189A - 189A
  • [8] Changes in flow mediated vasodilatation during antihypertensive treatment are related to the smoothness index, but not the trough-to-peak ratio of blood pressure
    Muiesan, ML
    Rizzoni, D
    Salvetti, M
    Porteri, E
    Monteduro, C
    Paini, A
    Poisa, R
    Bonzi, B
    Galbassini, G
    Agabiti-Rosei, E
    [J]. JOURNAL OF HYPERTENSION, 2005, 23 : S158 - S158
  • [9] ONCE-DAILY FIXED COMBINATION CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE (50/25 MG) IN THE TREATMENT OF MILD-TO-MODERATE ESSENTIAL-HYPERTENSION
    MALATINO, LS
    STANCANELLI, B
    GRECO, G
    BOTTA, G
    TAMBURINO, G
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1987, 41 (05): : 625 - 630
  • [10] Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine
    Paolo Palatini
    Ettore Malacco
    Salvatore Di Somma
    Renzo Carretta
    Francesca Dorigatti
    Federico Bertocchi
    Jessica Mann
    [J]. European Journal of Clinical Pharmacology, 2002, 57 : 765 - 770